Immunization, Vaccines and Biologicals

Diphtheria

Diphtheria is an infectious disease caused by the bacterium Corynebacterium diphtheria, which primarily infects the throat and upper airways, and produces a toxin affecting other organs. The illness has an acute onset and the main characteristics are sore throat, low fever and swollen glands in the neck, and the toxin may, in severe cases, cause myocarditis or peripheral neuropathy.. The diphtheria toxin causes a membrane of dead tissue to build up over the throat and tonsils, making breathing and swallowing difficult. The disease is spread through direct physical contact or from breathing in the aerosolized secretions from coughs or sneezes of infected individuals.

Vaccination against diphtheria has reduced the mortality and morbidity of diphtheria dramatically, however diphtheria is still a significant child health problem in countries with poor EPI coverage. In countries endemic for diphtheria, the disease occurs mostly as sporadic cases or in small outbreaks. Diphtheria is fatal in 5 - 10% of cases, with a higher mortality rate in young children. Treatment involves administering diphtheria antitoxin to neutralize the effects of the toxin, as well as antibiotics to kill the bacteria.

Diphtheria vaccine is a bacterial toxoid, ie. a toxin whose toxicity has been inactivated. The vaccine is normally given in combination with other vaccines as DTP vaccine or pentavalent vaccine. For adolescents and adults the diphtheria toxoid is frequently combined with tetanus toxoid in lower concentration (Td vaccine).

WHO recommends a 3-dose primary vaccination series with diphtheria toxoid, followed by a booster dose.

  • In countries that are rendered non-endemic through high immunization coverage, the primary vaccination series of 3 doses should be extended by at least 1 booster dose.
  • Revaccination of adults against diphtheria (and tetanus) every 10 years may be necessary to sustain immunity in some epidemiological settings. Particular attention should be given to revaccination of health-care workers.
  • To further promote immunity against diphtheria, diphtheria toxoid and tetanus toxoid rather than tetanus toxoid alone should be used when tetanus prophylaxis is needed following injuries

WHO position papers

Disease burden and statistics

Vaccine topics

Partners

Further information

Last updated: 26 February 2014

Highlights

Call for Consultants

IPAC - Call to Action

To renew investment in ISCL